RE:RE:RE:I sure like this JonThe Midatech deal appeared to be set up in a way that Midatech would acquire Bioasis but the xB3 platform would be sold off to private interests. (Midatech stated that Biodexa would not remain in the drug delivery business. xB3's only purpose is the delivery of drugs across the BBB.)
I'm not sure that Rathjen would be interested any longer in the niceties of that scenario. My guess is that Bioasis shareholders would likely get a little cash (3¢ or 4¢) and have no residual interests in xB3.
There could be another Midatech-type deal where the shareholders could get shares in the buying company, whether by RTO or however, but my guess is that the buying company would offload Rathjen, Saltarelli and the xB3 platform to private interests, the same as with the Midatech/Biodexa deal.
The tragedy of course is that Bioasis shareholders, with either scenario, won't get any benefit from xB3. The thing is, nobody will buy xB3, at any price if it doesn't work unless some market players acquire it to promote a pump and dump. xB3 could fuel a pump and dump because the case can be made that all studies have shown that it works.
This will remain an interesting story for at least the next two years. Patent clocks are ticking and the new owners will need to get things done in order to make a story of this. Billions per year in revenue may be at stake.
jd